Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) had its price objective decreased by equities researchers at HC Wainwright from $12.00 to $11.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target points to a potential upside of 154.63% from the stock's previous close. HC Wainwright also issued estimates for Y-mAbs Therapeutics' Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.92) EPS.

A number of other research firms have also recently weighed in on YMAB. Wedbush restated an "outperform" rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Bank of America downgraded Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a research report on Tuesday, April 22nd. Morgan Stanley decreased their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th. Oppenheimer lowered their target price on Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Finally, Truist Financial lowered their target price on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Two analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Y-mAbs Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.60.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB traded up $0.19 on Monday, hitting $4.32. 324,293 shares of the company's stock were exchanged, compared to its average volume of 311,779. The firm's 50-day moving average price is $4.41 and its two-hundred day moving average price is $6.74. Y-mAbs Therapeutics has a fifty-two week low of $3.55 and a fifty-two week high of $16.11. The firm has a market cap of $195.63 million, a price-to-earnings ratio of -8.00 and a beta of 0.53.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $20.90 million for the quarter, compared to analysts' expectations of $19.97 million. On average, research analysts predict that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now directly owns 202,721 shares of the company's stock, valued at approximately $1,060,230.83. The trade was a 5.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 22.50% of the company's stock.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Acorn Capital Advisors LLC increased its position in shares of Y-mAbs Therapeutics by 13.1% during the first quarter. Acorn Capital Advisors LLC now owns 3,235,387 shares of the company's stock worth $14,333,000 after acquiring an additional 373,562 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Y-mAbs Therapeutics by 58.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 237,511 shares of the company's stock worth $1,052,000 after purchasing an additional 87,830 shares in the last quarter. AQR Capital Management LLC grew its stake in Y-mAbs Therapeutics by 869.3% in the first quarter. AQR Capital Management LLC now owns 164,788 shares of the company's stock worth $730,000 after purchasing an additional 147,788 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in Y-mAbs Therapeutics by 223.9% in the first quarter. Cubist Systematic Strategies LLC now owns 155,522 shares of the company's stock worth $689,000 after purchasing an additional 107,511 shares in the last quarter. Finally, Stonepine Capital Management LLC acquired a new position in Y-mAbs Therapeutics in the first quarter worth about $581,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.